Immunohistochemical localization of granzyme B in peritumoral infiltrates of basal cell carcinoma (letter)

Published in:
British journal of dermatology

DOI:
10.1111/j.1365-2133.1997.tb01570.x

Citation for published version (APA):
Correspondence

The diagnostic value of polymerase chain reaction in erythema induratum of Bazin

Sir, Erythema induratum of Bazin (EIB) is a chronic, nodular eruption that usually occurs on the lower legs of women with tuberculin hypersensitivity. The etiopathogenetic association between EIB and tuberculosis is still controversial.1

A 38-year-old woman presented with recurrent crops of tender, painful, non-ulcerating erythematous nodules occurring on the lower third of her left calf and shin over the last 5 years (Fig. 1). She had no personal or family history of active tuberculosis and had received a BCG vaccination during childhood. Forty-eight hours after a purified protein derivative test, an erythematous induration of 2.5 cm × 2.5 cm was observed at the test site. Tests for the diagnosis of tuberculosis showed a normal chest X-ray, and were negative for acid-fast bacilli in the sputum. Tests for the diagnosis of tuberculosis showed a normal chest X-ray, and were negative for acid-fast bacilli in the sputum. Mycobacterial culture of a skin specimen and sputum proved negative, and bacterial culture of the skin specimen was also negative. Histopathology revealed an infiltration of mononuclear cells which was most prominent in the fat lobules, multinucleate giant cell granulomas and perivascular inflammation in some areas of the subcutis. Ziehl–Neelsen staining for acid-fast bacilli was negative.

To investigate the possible relationship between EIB and Mycobacterium tuberculosis, polymerase chain reaction (PCR) of the biopsy specimen was carried out using a method described by Eisenach et al.2 The biopsy specimen was digested in a buffer (200 μg/mL proteinase K in 50 mmol/L Tris–HCl pH 8.5) for 6 h at 55 °C and boiled for 10 min. Phenol–chloroform extraction was performed and ethanol precipitated DNA was resuspended in TE buffer (10 mmol/L Tris–HCl, 1 mmol/L ethylenediamine tetraacetic acid, pH 7.4) and used for amplification. The sequences of the primers (5’ to 3’) were CCTGCGAGGTAGGCCTCGG and CTGTCAGGCGCGCTCGG. Amplification reactions were performed by using Taq polymerase and reagents according to the manufacturer’s instructions (Promega, Madison, WI, U.S.A.). Five microlitres of DNA were added to the mixture. The reaction was run for 40 cycles with denaturation at 94 °C for 2 min, annealing at 68 °C for 2 min and extension at 72 °C for 2 min in a thermal cycler (MJ Research, Watertown, MA, U.S.A.). PCR products were analysed by gel electrophoresis on a 2% agarose gel stained with ethidium bromide and visualized by ultraviolet light. A PCR product of 123 bp diagnostic for M. tuberculosis DNA was obtained (Fig. 2). The patient was given antituberculosis chemotherapy consisting of isoniazid, rifampicin and pyrazinamide and was free of lesions after the first month of treatment.

Tuberculosis is still a very important infectious disease world-wide, especially in developing countries. Early detection and accurate diagnosis of tuberculosis and related diseases are of major importance in the control of this disease. EIB has been accepted as a type of tuberculid that usually occurs on the legs of middle-aged women, possibly after haematogenous spread of a few mycobacteria.1,3 The tuberculous origin of EIB is controversial since mycobacteria cannot be cultured from the skin lesions.1,3

EIB is one of a group of diseases that primarily involve the legs and are characterized by the presence of inflammatory nodules. These diseases have many clinical and/or histopathological features in common (e.g. EIB, erythema nodosum, nodular vasculitis, pernio, polyarteritis nodosa, subacute nodular migratory panniculitis, syphilitic gummata and recurrent idiopathic thrombophlebitis).1,3 It may sometimes therefore be difficult to reach the diagnosis of EIB.

Figure 1. Erythema induratum of Bazin. Non-ulcerating erythematous nodules can be seen on the calf. The punch biopsy site is on the right.
In addition, a positive Mantoux reaction is usually not helpful in making the diagnosis, since BCG vaccination is the rule in Turkey.

PCR technology has been used to detect *M. tuberculosis* DNA from different kinds of cutaneous tuberculosis, including lupus vulgaris,4–6 scrofuloderma,6,7 orificial tuberculosis,6 and disseminated tuberculosis.6 *M. tuberculosis* complex DNA was also found by PCR in lesions of papulonecrotic tuberculid8 and EIB.8–10

PCR is a powerful method for making or confirming the diagnosis of cutaneous tuberculosis and determining the tuberculous origin of tuberculids. We believe that the presence of relevant clinicopathological findings and a positive Mantoux reaction should not be sufficient to start antituberculosis chemotherapy, especially in countries where this reaction does not have a great value. We suggest that the tuberculous origin of tuberculids be confirmed by using PCR in order to start appropriate treatment early and avoid the improper use of complex and potentially toxic drug regimens.

Acknowledgments

The authors wish to thank Dr Namik Ozbek and Gultekin Erdogan for their help in the preparation of this correspondence.

References


Immunohistochemical localization of granzyme B in peritumoral infiltrates of basal cell carcinoma

Sm, Basal cell carcinomas (BCCs) are frequently associated with peritumoral mononuclear cell infiltrate that may represent a specific antitumour response.1,2 The infiltrate largely consists of T cells with a predominance of the CD4+/T− helper over the CD8+/T-cytotoxic (Tc) subset, together with small numbers of natural killer (NK) cells.3 Several studies have shown expression of activation markers on 30–50% of T cells in BCC.4,5 Regression of BCC, either spontaneously or after local immunotherapy, correlates with increased numbers and activation state of peritumoral T cells, whereas aggressive tumour behaviour is associated with decreased numbers of T cells in peritumoral areas.6 Although these data suggest a cell-mediated antitumour response, the role of cells with cytolytic potential, i.e. Tc and NK cells, in immune surveillance of BCC, is not clear. The presence of characteristic granules in the cytoplasm of Tc cells and NK cells correlates with activation and subsequent cytolytic potential of these cells in vitro. These cytolytic granules contain a pore-forming protein, perforin, and several homologous serine proteinases called granzymes. The action of granzymes results in the apoptotic death of the target cell.7–10

Our objective was to study the expression of granzyme B (grB) by cells present in immune infiltrates surrounding BCC, as an indicator of cytolytic activity against the tumour.

On formalin-fixed, paraffin-embedded specimens, we investigated the expression of grB in 10 patients with BCC, of whom eight were untreated and two had been treated once with intralesional interferon (IFN)-α2b. Single- and two-colour staining with anti-CD3 or anti-CD8 antibodies was performed to identify the phenotype of grB-positive cells. Cells displaying a strong cytoplasmic granular staining were considered grB-positive. Immune infiltrates of BCC were compared with those of squamous cell carcinoma (SCC, n = 5), melanoma (n = 4) and inflamed seborrhoeic keratosis (SK, n = 3).

Despite the presence of large numbers of CD3+ and CD8+ T cells, there was an almost striking absence of grB-positive cells in peritumoral BCC areas (Fig. 1a). The limited number of cells that expressed grB did not co-express CD3 or CD8 and consequently represented NK cells. GrB-positive NK cells were scattered mainly throughout the peritumoral stroma, but did not infiltrate the tumour lobules. Larger numbers of grB-positive NK cells as well as sporadic grB-positive Tc cells were present inside or close to capillary lumina, distant from the tumour islands. In the two cases of BCC treated with IFN-α2b 48 h prior to resection, the number of grB-positive NK cells in perivascular areas appeared to be increased. In contrast with BCC, SCC, SK and melanoma showed significant numbers of grB-positive NK cells not only 'crowding' directly adjacent to the tumour, but also invading tumour islands (Fig. 1b). The number of grB-positive Tc cells in these conditions was small, although increased compared with BCC.

In this study, we investigated the possible role of Tc cells and NK cells as active participants in immune surveillance towards BCC, by analysis of grB expression. The majority of
peritumoral Tc cells did not express grB, while only a limited number of grB-positive NK cells was present. The expression of grB can be used as a specific functional marker for activated Tc cells in vivo, i.e. grB characterizes a specific T-cell population that has been stimulated by recognition of its target. These T cells possess lytic potential. We conclude that in patients with BCC, the ‘activated’ state of peritumoral T cells apparently does not lead to expression of granzymes and subsequent cytolytic activity by cytotoxic T cells present in these infiltrates.

Acknowledgements

Monoclonal antibody GrB7 was a kind gift of Prof. C.E.Hack from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service in Amsterdam.

Department of Dermatology, University Hospital Maastricht, Maastricht, The Netherlands
*Renal Transplant Unit AMC, University of Amsterdam, Amsterdam, The Netherlands

References


Histidinohydroxylysinoonorleucine, a trifunctional cross-link of type I collagen, in sun-exposed and sun-protected human skin

Sir, Histidinohydroxylysinoonorleucine (HHL), a non-reducible trifunctional collagen cross-link derived only from type I collagen in mature bovine or human skin, was recently identified.1,2 This stable intermolecular cross-link that binds three amino acid residues of two collagen α1(I) chains and one collagen α2(I) chain, is assumed to provide collagen fibres with their stability and physiochemical properties.3 A conventional method using amino acid analysis has been carried out for the HHL measurement in human skin.1,4 This method, however, is time-consuming and requires a large amount of skin. We have developed a novel high-performance liquid chromatography (HPLC) system which enables the measurement of the HHL content in small samples at a picomole order.5

A 6-mm punch biopsied skin sample was obtained from six healthy volunteers over 70 years of age. Approximately 1 mg of lyophilized dermis was hydrolysed after pulverization. Twenty-five microlitres of the skin hydrolysate, diluted in borate buffer (amino acid concentration: 0.25 mmol/L), 25 µL of 3 mmol/L N6-methyl-L-lysine-HCl as an internal standard, 25 µL of water and 50 µL of acetone, were mixed, and 6 mmol/L 9-fluorenylethyl chloroformate (FMOC-Cl) in acetone was added at room temperature. After extraction with pentane, the aqueous phase was subjected to HPLC using Inertsil ODS-2 stainless steel column (4.5 × 150 mm, GL Sciences, Tokyo, Japan). FMOC-Cl derivatives were detected fluorescing. A gradient elution system with 40 or 60% acetonitrile in 0.3% acetic acid buffer containing 0.08 mmol/L NaCl (pH 4.7) was employed. Hydroxyproline was also determined by HPLC, according to the previous method.6

The peak of HHL was clearly detected and linearity for HHL referred to an internal standard was confirmed from 1 to 10 pmol. The HHL content was expressed as a molar ratio to collagen (mol/mol) calculated on the basis of 300 residues of hydroxyproline in one collagen molecule. As shown in Table 1, the HHL content in the sun-exposed site (0.29 ± 0.05; mean ± SD) was significantly decreased in comparison to the sun-protected site (0.56 ± 0.09; mean ± SD).

Table 1. HHL content in sun-exposed and sun-protected sites as measured by HPLC

<table>
<thead>
<tr>
<th>Ratio of HHL/collagen (mol/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
</tbody>
</table>

Mean ± SD 0.29 ± 0.05; mean ± SD 0.50 ± 0.09

ND, not determined; †P < 0.002.
with that of the sun-protected site (0.50 ± 0.09) (P < 0.002 by Student’s t-test).

It has been demonstrated that the amount of HHL gradually increases from birth to the fifth decade of life, presumably reflecting skin maturity, and decreases in sun-exposed skin from birth to the fifth decade of life, presumably reflecting skin maturity, and decreases in sun-exposed skin when compared with sun-protected skin. Inflammatory cells in ultraviolet-irradiated skin were assumed to hydrolyse collagen enzymatically. In this context, ultraviolet B irradiation induces the production of tumour necrosis factor-α (TNF-α) by keratinocytes, and then TNF-α stimulates collagenase activity and inhibits collagen gene transcription by fibroblasts.

These observations suggest that collagen degradation in the skin may be accelerated by ultraviolet irradiation (e.g. photolysis and impediment of HHL formation). However, in vitro experiments revealed that the HHL structure itself was resistant to ultraviolet A or B irradiation. Therefore, it is conceivable that the decreased amount of HHL in sun-exposed skin is indirectly caused by the degradation of collagen peptides other than HHL. Alternatively, there may be a site difference rather than a difference due to photodamage. Our preliminary data on the HHL content in swine skin suggested that site difference is the explanation (data not shown).

The measurement of HHL content with high sensitivity is an absolute requirement when investigating the metabolism of HHL in vivo and in vitro. The present study clearly indicates that our novel method is applicable to this purpose and is promising for use in future studies of cutaneous ageing for the measurement of collagen cross-links.

Department of Dermatology, K OKADA
Gunma University School of Medicine, A KONDO
Maebashi 371, Japan, O ISHIKAWA
E-mail: kokada@sb.gunma-u.ac.jp Y MIYACHI

References


Computed tomography reveals thickened subcutaneous tissue in scleroedema

Sir, Scleroedema adultorum is a connective tissue disease of unknown aetiology, which is clinically characterized by diffuse, non-pitting oedema and induration of the skin. A thickened dermis with large spaces between collagen bundles has been well known as the pathological hallmark of this disease. Although it is suggested that the subcutaneous tissue is involved, no morphological evidence has been demonstrated. We recently suggested the involvement of six scleroedema patients by computed tomography (CT), and found that the subcutaneous tissue was significantly increased in thickness.

We studied six patients with scleroedema (four men and two women, mean ± SD age 48 ± 4.8 years) and 35 control

Figure 1. The CT image of a scleroedema patient (a) and of a normal control (b). The dermis (D) and subcutaneous fatty tissue (S) of the former are thicker than the latter. R, right; L, left.

© 1997 British Association of Dermatologists, British Journal of Dermatology, 137, 1011–1031
patients with non-dermatological diseases (18 men and 17 women, mean ± SD age 56.9 ± 13.7 years) (Table 1). Diabetes mellitus was present in five scleroderma patients, and was of the non-insulin-dependent type in four. When the body mass index (BMI) was calculated as weight (kg)/height^2 (m^2), it was found to be at least 25 in all scleroderma patients. The control patients were divided into nine patients who had BMI of more than 25 (abbreviated as >25 obese controls) and 26 who had a BMI of less than 25 (abbreviated as 25 obese controls). By using CT, the thickness of the dermis and subcutaneous tissue was determined at the level of the seventh cervical vertebra. A comparison was made between the scleroderma and the control patients (Fig. 1), using the Mann–Whitney test.

In the CT images, the mean thickness (± SD) of subcutaneous tissue was 28.8 ± 8.91 mm in the six scleroderma patients and 16.3 ± 6.56 mm in BMI >25 obese controls. The former was significantly greater than the latter (P = 0.006). The average BMI was not significantly different between scleroderma patients (26.9 ± 2.70) and the BMI >25 obese controls (28.6 ± 0.90, P = 0.182). Furthermore, the thickness of subcutaneous tissue did not significantly differ between the BMI >25 obese controls (16.3 ± 6.56 mm) and BMI 25 obese controls (15.7 ± 7.94 mm P = 0.317). When the dermis was measured by CT, the mean (± SD) thickness was 7.95 ± 1.70 mm in the scleroderma patients and 2.51 ± 0.65 mm in the controls. The former was significantly thicker than the latter (P < 0.001).

Our study has demonstrated that the subcutaneous tissue was significantly thicker in the involved areas of scleroderma compared with the normal-appearing skin of obese controls. As the thickness of the subcutaneous tissue was not significantly different between obese and non-obese controls, the thickening is likely to be a specific finding in scleroderma adultorum. Our CT study also demonstrated that the dermis is much thicker in scleroderma patients than in controls. The thickened dermis has been confirmed histologically^3 and in terms of image analysis using ultrasound scan.4 The skin in scleroderma adultorum is often slightly elevated and swollen,5 a clinical feature that may be associated with thickened subcutaneous tissue.

Fibrotic skin fibroblasts from a non-diabetic scleroderma patient have been demonstrated to show an increase in total collagen synthesis and in type I collagen mRNA, and to show enhanced collagen production and elevated type I procollagen mRNA in a diabetic scleroderma patient.6 The thickening of the subcutaneous tissue may be explained by increased collagen and mucin deposition in the septum. Furthermore, in scleroderma associated with non-insulin-dependent diabetes, the increased amount of insulin may stimulate the nuchal fibroblasts and pre-adipocytes and thereby increase the quantity of collagen fibres and adipose cells.7 In our study, five patients had diabetes of whom four were non-insulin-dependent. A recent report has demonstrated that glucose intolerance had greater influence on the upper body segment than on the lower body segment.8 Such a finding is consistent with the evidence that the subcutaneous tissue is usually thickened in the upper body segment in diabetic scleroderma.

Table 1. Summary of clinical features of patients with scleroderma and control patients

<table>
<thead>
<tr>
<th></th>
<th>Age (years) mean ± SD</th>
<th>Body mass index (BMI) mean ± SD</th>
<th>Thickness of subcutaneous tissue (mm) mean ± SD</th>
<th>Thickness of dermis (mm) mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>48.2 ± 14.8</td>
<td>26.9 ± 2.70</td>
<td>28.8 ± 8.91</td>
<td>7.95 ± 1.30</td>
</tr>
<tr>
<td>Obese controls</td>
<td>62.0 ± 15.3</td>
<td>28.6 ± 0.90</td>
<td>16.3 ± 6.56</td>
<td>2.51 ± 0.65</td>
</tr>
<tr>
<td>Normal controls</td>
<td>56.9 ± 13.7</td>
<td>20.9 ± 7.01</td>
<td>15.7 ± 7.94</td>
<td></td>
</tr>
</tbody>
</table>

1 Body mass index is calculated by weight (kg)/height^2 (m).
2 These controls are from other CT studies.

References
Lamellar ichthyosis is markedly improved by a novel combination of emollients

Sir, Lamellar ichthyosis (LI) is a rare, congenital genodermatosis characterized by generalized hyperkeratosis, intense dryness of the skin, and large scales especially over the extremities. Although usually not life threatening, the disease can be very disfiguring and causes considerable distress to sufferers throughout life. The treatment of LI involves the use of oral vitamin A derivatives (retinoids) and various topical emollients such as urea, propylene glycol and alpha-hydroxy acids (AHA). Unfortunately, the therapeutic results are often meagre and associated with side-effects. In trying to improve therapy, one of us (A.G.), by serendipity, noted in her own children suffering from LI, that a mixture of 5% lactic acid and 20% propylene glycol in a commercially available cream base (Locobase®, Lipobase®, Yamanouchi, The Netherlands) was clearly superior to previously used emollients. Since a search in the literature revealed no data on an identical formulation, we conducted the following open study.

Ten patients (seven women, three men; age 2–38 years) with severe LI (two of whom had ongoing treatment with oral acitretin, 50–75 mg/day) were recruited after informed consent. Instead of applying their ordinary creams containing 5–10% urea or 3–10% lactic acid, the patients were instructed to apply the new formulation (see above) twice daily to the legs. Signs of scaling, hyperkeratosis and xerosis were separately scored (0–4) and the sums of scores (maximum: 12) were calculated for each patient before and after changing therapy. The use of the new formulation resulted, after 1 month, in a reduction of the mean (SD) total score from 9.6 (2.2) to 3.5 (2.3) (P < 0.001; paired t-test). All patients reported increased shedding of scales after a few days’ treatment, followed within 1–2 weeks by the appearance of a much smoother, almost normal-looking skin (Fig. 1). Nine patients considered the effect ‘better than ever obtained before’, and later chose to extend the treatment to the rest of the body with equally good results. One patient was able to reduce her acitretin dosage from 75 to 25 mg daily without deterioration of skin symptoms. Although some patients experienced a transient skin irritation after applying the cream, only one patient stopped therapy because of this. No other side-effects were noted.

Van Scott and Yu pioneered the use of AHA for ichthyotic conditions. They also described a keratolytic gel (5–10% AHA in water, ethanol and propylene glycol—4:4:2), the use of which fell into oblivion as it was irritating and unsuitable for whole body application. A better-tolerated, although still somewhat irritating formulation, is Lac-Hydrin® cream (Westwood-Squibb Pharm. Inc., Buffalo, NY, U.S.A.) containing 12% ammonium lactate in a propylene glycol-containing base. The combination of only 5% lactic acid and 20% propylene glycol in a lipophilic cream base (Locobase®, Lipobase®) is, in our experience, readily accepted by most patients and much more effective, and less irritating than monotherapy with either compound at twice these concentrations. The potent effect of this mixture suggests that the ingredients act synergistically in reverting hyperkeratosis. How this relates to the pathogenesis of LI is unclear. One recently detected cause of LI is deficiency of epidermal transglutaminase, a cross-linking enzyme essential for the formation of cornified cell envelopes. Hypothetically, lactic acid, which reduces ambient pH, hydrates keratins and dissociates cells in the lower stratum corneum, and propylene glycol, which dissolves other compounds, increases skin penetration and detaches corneocytes from the skin surface, might cooperatively stimulate remaining enzyme activities and restore

Figure 1. A 12-year-old boy with lamellar ichthyosis due to transglutaminase deficiency, showing (a) the situation before and (b) after 1 month of switching from 5% lactic acid in Locobase® to 5% lactic acid and 20% propylene glycol in Locobase® twice daily.

© 1997 British Association of Dermatologists, British Journal of Dermatology, 137, 1011–1031
a more normal skin desquamation (for a review see Rawlings et al.). In an ongoing clinical trial, we are trying to establish the optimal composition of a lactic acid/propylene glycol-containing lipophilic cream for use in different ichthyotic conditions, and are attempting to elucidate its mechanism of action.

Department of Dermatology, University Hospital, 751 85 Uppsala, Sweden

References

Venous lakes treated by liquid nitrogen cryosurgery

Sn, The venous lake, a ‘blueberry on the lip’, is a common variation of venous ectasia that occurs on the lips1 (Figs 1a and c). It is formed from a thin layer of epithelial cells and supported by a strong fibrous wall. Hence, it is not a true haemangioma, in spite of its common name of ‘senile haemangioma of the lip’.2 Its importance is not limited to the cosmetic, as trauma may result in profuse bleeding. The literature on the treatment of venous lakes is limited, but includes surgical excision, electrodesiccation, cryosurgery, laser therapy3 and infra-red coagulation.4 The technique and results of cryosurgery are published but are not widely known.5,6

The use of cryosurgery for venous lakes is based on tissue selectivity. The cryoprobe technique, also known as contact therapy, is quick and relatively simple. Cryosurgery is based on the rapid cooling of tissue with liquid nitrogen. The temperature changes cause disintegration of the cell membranes. Vasocostriction, then vasodilatation, and microthrombosis in the capillaries and arterioles lead to partial ischaemic necrosis.7

Deep destruction of tissue, as is needed for the treatment of a malignant lesion, is not desirable. Overfreezing is avoided and a single freeze–thaw cycle is sufficient. No local anaesthetic is needed, and protection of the lip is unnecessary. The cryoprobe is placed onto the lesion, pressed against it to compress the blood within, and the lesion is frozen together with a 1–1.5 mm rim of normal tissue. The probe is generally precooled, so that it does not adhere to the lip. The duration of cooling (freeze time) is 5–15 s, depending on the size of the lesion.

There is no visible damage to the tissue during or immediately after freezing. Oedema occurs after several minutes, with later bulla formation or sloughing. The patient may experience discomfort but pain is tolerable and eating or washing is not affected. Wound healing occurs after 2–3 weeks without discoloration of the lip or scarring (Figs 1a and b). In larger lesions, or after repeated treatments, some scarring may develop (Figs 1c and 1d) which is smooth and improves with time.

In addition to a hand-held unit containing liquid nitrogen, the most important instrument is a cryoprobe. Different sizes of round closed probes are available commercially but can also be made by a skilful technician. The contact surface consists of a thin flat copper or brass plate, 0.2–0.3 mm in diameter, so that cooling is rapid and easily controlled. The probes of diameters 2–5 mm, or 8 mm, are best. Luer-mount probes

Figure 1. (a) Typical venous lake on the lower lip before cryosurgery. (b) Complete healing after 3 weeks. Note the normal colour and surface texture of the lip. (c) An unusually wide venous lake on the upper lip was treated in sections by overlapping the freezing. (d) Good functional and aesthetic results at 2 months after two treatment sessions. There is no palpable scarring.
and adapters allow the use of cryosurgical devices with a non-standard mount. When using a contact probe, one should consider it as any other contact instrument and sterilize it after each use.

Cryosurgical treatment of venous lakes is safe, yields excellent results, is inexpensive, and suitable for most patients. It should not be used for those patients with cold-induced problems. The ice front should not extend beyond the vermilion margin as this can result in scarring or some loss of pigmentation.

Department of Dermatology, Mikkeli Central Hospital, Finland

References


Digital sympathectomy (microarteriolyis) in the treatment of severe Raynaud’s phenomenon secondary to systemic sclerosis

Sin, Raynaud’s phenomenon secondary to systemic sclerosis can become incapacitating. In the largest placebo-controlled double-blind trial of iloprost, 39% of patients experienced a decrease in Raynaud’s attacks (vs. 22% with placebo, P = 0.005). These results are in accordance with the clinical experience that nifedipine2,3 and iloprost can be effective in the short-term palliation of secondary Raynaud’s phenomenon but that there are many non-responders. We report on two patients with finger ulcers and intractable pain due to secondary Raynaud’s phenomenon. Both patients underwent digital sympathectomy and remained free of vasospastic symptoms for more than 2 years.

A 77-year-old woman presented with severe Raynaud’s phenomenon. A diagnosis of systemic sclerosis of the peripheral type was based on pathological capillaroscopy and a high titre of anticientromere antibodies. Progressive finger tip ulceration and intractable pain of the right index finger and middle finger did not respond to nifedipine (30 mg/day) and aspirin (100 mg/day) nor to intravenous iloprost therapy (2 ng/kg per hour for 6 h/day for 3 weeks). Systolic pressure was below 50 mmHg in both fingers, indicating critical ischaemia. Bilateral digital sympathectomy resulted in rapid relief of pain and recovery of digital systolic pressure.

An 82-year-old woman had had Raynaud’s phenomenon since youth. Two years ago, the attacks became more frequent and painful. She presented with the CREST-syndrome. A diagnosis of systemic sclerosis of the peripheral type was confirmed by the findings of giant nail-fold capillaries and a high titre of anticientromere antibodies (1:5120). She did not respond to nifedipine and aspirin and refused intravenous iloprost because of intolerable headaches under treatment. Finally, she requested amputation of her right index finger because of intractable pain and progressive finger tip necrosis.

One year later, severe vasospastic symptoms led to a comparable situation in the left index finger. Bilateral digital sympathectomy resulted in complete disappearance of pain. The finger tip necrosis healed within 4 weeks and the Raynaud’s phenomenon improved substantially for more than 2 years.

Intractable pain, finger tip necrosis and finger contractures can be part of Raynaud’s phenomenon secondary to systemic sclerosis. General measures include protection from cold temperature exposure and cessation of smoking. Nifedipine and prostaglandins such as iloprost are often effective in the treatment of secondary Raynaud’s phenomenon.1–3 but there remain many non-responders.

After upper dorsal thoracic sympathectomy (ganglia T2–T4), most patients have initial improvement of Raynaud’s phenomenon, but a relapse almost always occurs 6 months after the operation.4,5 During the last 10 years, thoracoscopic upper dorsal sympathectomy has rapidly gained ground in the treatment of palmar hyperhidrosis.6 For unknown reasons, the long-term results for primary hyperhidrosis of the palms are excellent, whereas long-term results for secondary Raynaud’s phenomenon are less consistent. Claes et al. observed that patients with sympathectomy due to hand sweat experienced warm hands for 6 months. After this period the temperature normalized without recurrence of hyperhidrosis.7,8 Flatt and others hypothesized that relapses were probably due to sympathetic reinnervation of the brachial plexus (C4–T3) via communicating nerve fibres.

For this reason, Flatt introduced the technique of digital artery sympathectomy.6 The adventitia of the digital arteries is surgically removed over a length of 4 mm. Eight patients with digital vascular insufficiency from different causes experienced symptomatic relief after this procedure.8 Electron microscopy confirmed that unmyelinated axons were present in the adventitia removed. Wilgis extended the procedure to a length of 2 cm and reported pain relief and ulcer healing in eight of nine patients.9 O’Brien et al. reported pain relief and ulcer healing in all of 11 patients with systemic sclerosis.10 They removed the adventitia of all palmar arteries (radical microarteriolyis) including the distal ulnar artery, superficial palmar arch and the digital arteries. If the ulnar artery were occluded, a venous bypass was inserted. In contrast to thoracic sympathectomy no (or only minor) recurrences of Raynaud’s phenomenon are seen after digital sympathectomy.9,10 Kaarel et al. investigated digital sympathectomy in monkeys. They showed that adrenergic nerves distal to the site of the
operation remained normal after removal of the adventitia, and hypothesized that the removal of the thickened adventitia from the vasospastic arteries was mainly responsible for the positive effect. For this reason, O’Brien et al. suggested that the term ‘microarteriolysis’ be used instead of ‘digital sympathectomy’. However, the term ‘digital sympathectomy’ might be more meaningful to physicians as well as to patients who are not familiar with hand surgery.

Our two cases confirm the studies mentioned above and show that digital sympathectomy (or microarteriolysis) is an effective tool in the treatment of critical ischaemia associated with secondary Raynaud’s phenomenon and might prevent the need for amputation.

References


Solid persistent facial oedema (Morbihan’s disease) following rosacea, successfully treated with isotretinoin and ketotifen

Sn. The onset of lasting, erythematous, non-pitting oedematous plaques on the upper half of the face is a well-known complication of acne vulgaris and is usually described in the literature as ‘solid persistent facial oedema’ (SPFO). A similar clinical condition has been reported in association with rosacea or without any apparent cause with the names of chronic lymphoedema of rosacea, chronic erythematous facial oedema or Morbihan’s disease. Recently, Holde and colleagues suggested that SPFO, chronic lymphoedema of rosacea and Morbihan’s disease should be considered as the same entity.

The histological features of SPFO are non-diagnostic, being characterized by oedema of the mid- and papillary dermis, dense perivascular and periadnexal lymphohistiocytic infiltrate with plasma cells and, in some cases, the presence of many mast cells. The pathophysiology of this disease is unknown and its treatment often unsatisfactory.

We have recently seen a 45-year-old man who presented with an eruption on his forehead of 12 months’ duration. A similar lesion of 1 month’s duration had developed on his right cheek. He was otherwise well apart from rosacea, present for 2 years, and the recent onset of a mild diabetes mellitus, controlled by diet. The patient had had mild acne vulgaris when younger. Examination showed a large erythematous oedematous plaque with poorly defined margin on the forehead (Fig. 1), and a smaller plaque on the right cheek. Both lesions contained a few pustules. On palpation, the skin was hard and elastic and did not pit. The lesions were asymptomatic but the patient had had transient episodes of swelling. Histopathological examination showed oedema of the papillary and mid-dermis, hypertrophic sebaceous glands and dense perivascular and periadnexal infiltrate composed of lymphocytes and histiocytes with many plasma cells. Toluidine blue staining revealed numerous mast cells. Routine blood chemistry, complement levels, tests for immune complexes, angiotensin-converting enzyme, lysozyme, anti-Leishmania anti-bodies and a skull X-ray were all normal or negative. A diagnosis of SPFO was made and the patient was started on isotretinoin, 0.7 mg/kg per day, with ketotifen, 2 mg/day, as previously recommended. After 4 months of this therapy, the lesion on the cheek had completely disappeared and the eruption on the forehead was substantially reduced.

Although SPFO following rosacea is rare, it should be included in the differential diagnosis of facial swelling. In our case, clinical, histological and laboratory data excluded diseases such as sarcoidosis, leishmaniasis, crysipelas, Merkelsono–Rosenthal disease and lymphoma, which may have a similar clinical appearance. The diagnosis of SPFO was also supported by the favourable outcome after combined therapy with isotretinoin and ketotifen. The present report confirms that this combination of drugs is efficacious in SPFO. However, clofazimine and isotretinoin are also said to be effective. Isotretinoin alone is beneficial in some cases, while drugs such as antibiotics, antihistamines and corticosteroids have been tried in a variety of combinations but do not appear to have any advantage over the use of isotretinoin with either ketotifen or clofazimine.

Department of Dermatology
of Siena University,
Viale Bracci, I-53100 Siena,
Italy
E-mail: mazzatenta@unisi.it

© 1997 British Association of Dermatologists, British Journal of Dermatology 137, 1011–1031
Figure 1. An oedematous plaque is evident on the forehead.

References

High-dose ranitidine is ineffective in the treatment of psoriasis

Sirs. Various treatments have been developed for psoriasis over recent decades, including the use of immunosuppressive agents.1 Recently, ranitidine, a histamine H2-receptor antagonist, has been reported to be of benefit in psoriasis.2–4 It is thought to work through an immunomodulatory action, although the exact mechanisms have not been delineated. This study was carried out to assess the efficacy of ranitidine in the treatment of psoriasis using a double-blind, placebo-controlled study design.

Fifty patients with stable, plaque-type psoriasis, involving up to 10% of the body surface, were enrolled in the study. They had received no topical or systemic treatment for the previous 4 weeks. Exclusion criteria included patients who were pregnant or lactating, or who had renal and hepatic disease. The research protocol was approved by the ethics committee of Akdeniz University, and all patients gave signed informed consent. Patients were randomly allocated to treatment groups equally, and received either placebo, or ranitidine, 300 mg, twice a day for 4 months. No concurrent topical or systemic treatments were allowed. Patients were evaluated at monthly intervals. At each visit, assessment of the severity of the disease was made by the same clinician, based on the psoriasis area and severity index (PASI). Differences in PASI scores between groups were tested using Student’s t-test and the Mann–Whitney U-test. To test the changes in groups from baseline to post-treatment, the paired t-test was used. Data are presented as means ± SEM. P<0.05 was considered to be statistically significant.

Fourteen ranitidine-treated and 14 placebo-treated patients completed the scheduled study period of 4 months, and were evaluated for efficacy of the treatment. Treatment groups were

| Table 1. Demographic and clinical characteristics of the treatment groups (mean ± SEM) |
|---------------------------------|------------------|------------------|
|                                  | Ranitidine (n = 14) | Placebo (n = 14) |
| Age (years)                      | 45.85 ± 4.57      | 34.92 ± 3.37     |
| Sex                              |                   |                  |
| Male                             | 9                 | 5                |
| Female                           | 5                 | 9                |
| Disease duration (years)         | 14.25 ± 3.5       | 10.96 ± 2.68     |
| PASI baseline                    | 12.31 ± 1.71      | 11.55 ± 1.17     |

© 1997 British Association of Dermatologists, British Journal of Dermatology, 137, 1011–1031
similar regarding sex and age. duration and severity of the
disease (Table 1). Twenty-two patients were withdrawn before
4 months because of failing to attend for review at the correct
times or for using prohibited concomitant medication. No
patient was withdrawn due to an adverse event or worsening
of the disease. The mean PASI scores in each group under-
going treatment are given in Fig. 1. Baseline and post-treat-
ment mean PASI scores were 12.31 ± 1.71 and 13.96 ± 2.13
in the ranitidine group and 11.55 ± 1.17 and 12.97 ± 1.53 in
the placebo group. No significant differences were noted
between the mean baseline and post-treatment PASI scores in
each treatment group. The mean PASI scores did not show any
statistically significant changes from baseline to first month,
first month to second month, second month to third month,
and third month to post-treatment in each group. In addition,
there were no statistically significant differences in the mean
baseline, first, second, and third post-treatment PASI scores
between the ranitidine and placebo groups.

In this randomized, double-blind study we have shown that
ranitidine is not effective in the treatment of psoriasis. Clinical
trials using H2-receptor antagonists in psoriasis have given
various degrees of success. Previous studies using cimetidine,
administered for a short time, were disappointing. In contrast,
Nielsen et al. and Witkamp et al. have reported beneficial effects for ranitidine given for 4 months. They suggested that long-term high-dose ranitidine improves psoriasis after a lag time of 1–3 months and that the unsuccessful results for cimetidine may be due to the short treatment period. Recently, Kristensen et al. reported the results of an open, uncontrolled study in which ranitidine was employed in a dosage of 600 mg/day for 6 months. The authors pointed out an initial deterioration of the disease in the first month of treatment. Subsequently, a statistically significant reduction at the mean PASI score was observed at the third month of treatment. In our study, seven patients in each group showed worsening of their disease within the first month of treatment, but an increase in the mean PASI scores in each group was not significant. No significant reductions were noted in mean post-treatment PASI scores in each group. In the present study, ranitidine did not produce an effect superior to that of placebo.

Cell-mediated immunity appears to play an important part
in the pathogenesis of psoriasis. Ranitidine might be expected to be effective in the treatment of psoriasis because of its immunomodulatory effects. Despite promising results of open and uncontrolled studies, we found that systemic rani-
tidine is not an effective alternative in the treatment of plaque-
type psoriasis.

Acknowledgments

The authors would like to thank the Research Foundation of Akdeniz University for financial support of this study, and Fako Ilaçlar A.Ş.-Ablar who supplied both placebo and ranitidine tablets.

Akdeniz University, LÇêtin
Medical Faculty, E.Yilmaz
Department of Dermatology, E.Alpsoy
07070 Antalya, Turkey E.Basaran

References


Focal neurological signs and symptoms induced by interferon-alpha in two patients with malignant melanoma

Snr, Interferon-alpha therapy is an approved treatment for metastatic malignant melanoma and an adjuvant treatment for high-risk malignant melanoma. The most common side-effects are fatigue and influenza-like symptoms; but a few patients have been reported with ischaemic reactions. We read with interest the article by Bachmeyer et al. and report two patients who had focal neurological signs and symptoms possibly induced by interferon-alpha. A 41-year-old man with no risk factors for vascular disease was treated for malignant melanoma with lymphoblastoid
interferon-alpha, 9 million international units (IU) subcutaneously (s.c.) on alternate days. Two months after the start of this treatment and about 2 h after an interferon injection, the patient suffered a cerebral stroke with paresis of the right arm and leg. Cranial computed tomography (CT) and nuclear magnetic resonance scans demonstrated an ischaemic area in the region of the pons. The symptoms improved gradually over a period of 6 months and no further event occurred. Interferon therapy was continued for another 10 months at a reduced dose of 3 million IU on alternate days. The patient died 31 months after the onset of interferon therapy due to widespread metastatic disease. No atherosclerotic plaques in cranial arteries or brain-stem metastases were demonstrated on post-mortem.

A 57-year-old woman with malignant melanoma, who had no risk factors for vascular disease, received combined chemoinmunotherapy with dacarbazine and recombinant interferon-alpha 2b (3 million IU s.c. three times a week). Five days after the start of treatment and 3 h after the interferon injection, she noticed weakness and sensory loss in the left forearm and hand. This completely resolved within 1 h. Two similar episodes occurred, which were more severe and extended to the left shoulder, 4 and 7 weeks later. Unfortunately, the patient did not consult a physician at the time. Detailed neurological examination several days after the last episode showed no abnormality and cranial CT scans were normal. The dose of interferon-alpha was reduced to 1 million IU three times a week and there have been no further neurological complaints after 10 months of follow-up.

We report two patients who experienced focal neurological signs and symptoms 2–3 h after s.c. interferon-alpha. Although there is no proof that this treatment directly caused the symptoms, the time sequence suggests an association. Our observation is in agreement with reports in which interferon-alpha has induced ischaemic reactions in various tissues. These include cutaneous necrosis at an injection site,2–5 Raynaud’s phenomenon and digital necrosis,3,6,7 ischaemia of the colon,8 and ischaemic optic neuropathy.9 To explain the pathogenesis of such reactions, Reid et al.6 postulate that interferon-alpha may cause a vasculitis resulting in acral necrosis. However, in both of our patients, as well as in other cases, inflammatory or allergic mechanisms due to the interferon are unlikely, as the treatment could be as well as in other cases, inflammatory or allergic mechanisms resulting in acral necrosis. However, in both of our patients, reduced dose of 5 million IU on alternate days. The patient died 31 months after the onset of interferon therapy due to widespread metastatic disease. No atherosclerotic plaques in cranial arteries or brain-stem metastases were demonstrated on post-mortem.

A 57-year-old woman with malignant melanoma, who had no risk factors for vascular disease, received combined chemoinmunotherapy with dacarbazine and recombinant interferon-alpha 2b (3 million IU s.c. three times a week). Five days after the start of treatment and 3 h after the interferon injection, she noticed weakness and sensory loss in the left forearm and hand. This completely resolved within 1 h. Two similar episodes occurred, which were more severe and extended to the left shoulder, 4 and 7 weeks later. Unfortunately, the patient did not consult a physician at the time. Detailed neurological examination several days after the last episode showed no abnormality and cranial CT scans were normal. The dose of interferon-alpha was reduced to 1 million IU three times a week and there have been no further neurological complaints after 10 months of follow-up.

We report two patients who experienced focal neurological signs and symptoms 2–3 h after s.c. interferon-alpha. Although there is no proof that this treatment directly caused the symptoms, the time sequence suggests an association. Our observation is in agreement with reports in which interferon-alpha has induced ischaemic reactions in various tissues. These include cutaneous necrosis at an injection site,2–5 Raynaud’s phenomenon and digital necrosis,3,6,7 ischaemia of the colon,8 and ischaemic optic neuropathy.9 To explain the pathogenesis of such reactions, Reid et al.6 postulate that interferon-alpha may cause a vasculitis resulting in acral necrosis. However, in both of our patients, as well as in other cases, inflammatory or allergic mechanisms due to the interferon are unlikely, as the treatment could be subsequently continued without further side-effects.4,5 Interferon-alpha may increase blood coagulability as, in two patients with digital necrosis, thrombotic occlusion of small dermal vessels without signs for inflammation has been reported.3 The induction of vasospasm by interferon-alpha is an alternative pathogenetic pathway supported by its induction of Raynaud’s phenomenon in some patients,3 and the dose-dependency of symptoms in our patients, lower doses being well tolerated.

As adjuvant high-dose therapy with interferon-alpha has been approved for patients with high-risk malignant melanoma in the U.S.A.1 and will very probably be approved in Europe soon, physicians and patients should be aware of the potential for severe ischaemic side-effects.

References

Subungual blue naevus

Sir, Blue naevi occur most commonly in the skin, but they have also been found in oral mucosa, the vagina, penis, sclera, uterine cervix and prostate.1–3 Blue naevus has not been previously reported to involve the nail apparatus.

We report a 20-year-old man who presented with a subungual pigmented lesion of the right great toe. The lesion had been progressively enlarging for several months prior to presentation. The diagnosis of blue naevus was made on histological examination showing a thick pigmented lesion with a cellular fibrous stroma.

During the few months prior to presentation, the nodule had increased in size and had become slightly painful. There was no history of trauma. Examination showed a pigmented subungual nodule, 0.9 cm in diameter, that extended to the distal phalanx. The nodule was firm and elevated from the nail plate (Fig. 1). The nodule showed regular bluish-black discoloration, emerging from under the nail edge, and involved the hyponychium. There was no lichenoid papule. The lesion was excised and histopathology demonstrated a subungual blue naevus, consisting of a thickened papillary dermis with hyperplasia and pigmentation of the epidermis and dermis.

1. Subungual blue naevus is an uncommon type of blue naevus that usually involves the skin. They have been reported to occur in various locations, including the oral mucosa, vagina, penis, and cervix. However, the occurrence of subungual blue naevus has not been previously documented.

2. The lesion was excised, and histopathology demonstrated a subungual blue naevus, consisting of a thickened papillary dermis with hyperplasia and pigmentation of the epidermis and dermis.

3. Subungual blue naevi are usually asymptomatic, but they can cause pain and tenderness. They are rarely associated with trauma.

4. The subungual blue naevus in this case was not associated with any significant systemic symptoms or signs.

5. Subungual blue naevi should be distinguished from other nail abnormalities such as melanonychia and onychomycosis.

6. Treatment options for subungual blue naevi include surgical excision and photodynamic therapy.

7. The patient was followed up for 6 months after the excision, and there were no signs of recurrence.

8. Subungual blue naevi are uncommon and tend to be asymptomatic. They are usually found in the skin, but cases have been reported in the oral mucosa, vagina, penis, and cervix.

9. The histopathological features of subungual blue naevi show hyperplasia and pigmentation of the epidermis and dermis.

10. The presence of hyperplasia and pigmentation in subungual blue naevi suggests a benign process.

11. The differential diagnosis of subungual blue naevi includes melanonychia and onychomycosis.

12. Surgical excision and photodynamic therapy are effective treatment options for subungual blue naevi.

13. The patient was followed up for 6 months after the excision, and there were no signs of recurrence.

14. Subungual blue naevi are a rare but distinctive type of blue naevus that involves the nail apparatus. They are usually asymptomatic and can be diagnosed by histopathological examination.
melanocytes were mostly orientated with their long axes parallel to the epidermis and many were filled with fine granules of melanin (Fig. 2). Numerous melanin-laden macrophages were interspersed among the melanocytes. The stroma of the lesion consisted of sclerotic collagen bundles surrounding aggregates of melanocytes. No melanocyte atypia or mitotic figures were seen.

Subungual blue naevus is not described in standard textbooks. Baran and Dawber illustrate a blue naevus involving the proximal nail fold of a great toe in a child as an example of pseudomalignancy in the differential diagnosis of subungual melanoma, a case supplied by Dr Kerl of the University of Graz, Austria. The patient was a 4-year-old girl with Klippel–Trenaunay syndrome, who showed a sharply demarcated irregular black area, 1.2×0.4 cm, involving the distal phalanx of the left first toe, with several pinhead-sized satellite nodules in the adjacent skin. The lymph nodes in the left groin were palpable. Amputation of the left big toe and dissection of the lymph nodes of the left groin were performed. The periungual lesion was shown on histology to be a combined naevus, comprising a Clark’s naevus at the dermoepidermal junction and a blue naevus in the dermis. Epithelioid dendritic and spindle-shaped melanocytes were found in the capsule and in some parts of certain lymph nodes. The case was interpreted as an example of a periungual combined naevus with ‘benign’ lymph-node metastases from the blue naevus component. We have studied these histopathology sections (provided by Dr Soyer of the University of Graz), and concur with the diagnosis. This patient is now 16 years old and remains well with no evidence of recurrence of metastatic disease. Salasche and Garland described a melanotic lesion involving the thumb nail, said to be a subungual blue naevus, but there was no histology.

The differential diagnosis of subungual melanocytic lesions should always include subungual malignant melanoma. In our case, melanoma in situ could be ruled out because no junctional melanocytic component was present and the findings in the dermis were typical for a blue naevus.

References
Idiopathic calcinosis cutis of the penis

Sirs, Calcinois of the scrotum is well documented, but calcinosis of the penis is rare. It usually affects the penile subcutis or corpora rather than the overlying skin. Of the few cases of penile calcification that have been reported, most have been secondary to a recognized underlying pathological process such as Peyronie’s disease, or have followed trauma and thus were dystrophic in nature. We present a patient with idiopathic dermal calcinosis of the penis. Similar clinical and pathological features have been described in only one previous case.

A 16-year-old boy was referred with an 8-month history of asymptomatic penile papules. He had no systemic symptoms and there was no history of trauma to the penis or of an inflammatory process in the penile skin. Examination revealed a 4-mm diameter smooth hard papule on the shaft of the penis, surrounded by a cluster of smaller papules (Fig. 1). General examination was normal. A diagnosis of inclusion cysts was made. The largest papule was biopsied, and histology showed a mass of calcified debris with focal ossification in the dermis, surrounded by a foreign body reaction with numerous giant cells and a rim of hyaline fibrous tissue (Fig. 2). There was no evidence of an epithelial cyst lining or an adnexal tumour. Routine haematological and biochemical tests were normal.

Calcification of the skin and other tissues can be classified into: dystrophic, metastatic and idiopathic. Dystrophic calcification is associated with an underlying tissue abnormality, metastatic with elevated levels of calcium or phosphate in the blood, but with idiopathic calcification, no underlying cause can be found.

Calcification of the penis is usually the result of dystrophic calcification and has been described in association with trauma, self-injection with papaverine for erectile impotence, and Peyronie’s disease, in which one or more irregular dense fibrous plaques occur on the penile shaft with varying degrees of calcification or ossification. Katoh et al. described a patient with a calcified penile nodule thought to result from calcification of a syringoma. Histological examination showed several foci of calcification, some, but not all, of which were surrounded by epithelial cyst walls. Metastatic calcification of the penis has been described in six of 32 patients with end-stage renal failure and secondary hyperparathyroidism who presented with erectile impotence. Our patient appears to have idiopathic calcification as no pre-existing lesion could be identified. In one previous similar case of idiopathic penile calcification, there was dermal calcification with no evidence of associated cysts nor remnants of adnexal structures.

The pathogenesis of idiopathic penile calcification may be similar to that proposed for idiopathic scrotal calcinosis, a more common disease that affects men of a similar age group to our patient. Several authors have suggested that scrotal calcinosis is the result of changes in pre-existing epidermal cysts or eccrine duct milia. The keratinous contents of such cysts become inspissated and undergo dystrophic calcification which results in attenuation and resorption of the cyst walls leaving the calcified material behind as a ‘tombstone’.

Department of Dermatology, Western Infirmary, Glasgow G11 6NT, U.K.

T. Lucke M. Fallowfield P. McHenry

© 1997 British Association of Dermatologists, British Journal of Dermatology, 137, 1011–1031
Eyelid metastasis as the presenting sign of recurrent carcinoma of the breast

SIR, Carcinoma of the breast frequently involves the skin, with cutaneous lesions being seen in about 25% of patients with metastatic disease. Up to eight distinct clinicopathological types of cutaneous involvement have been described for breast carcinoma, including metastatic eyelid disease.1 Metastatic breast carcinoma in the eyelid seems to be very rare, and only a few cases have been reported.2,3 We present a woman with carcinoma of the breast in whom eyelid metastasis was the presenting sign of recurrent disease.

A 52-year-old woman was admitted in June 1990 with a palpable mass measuring 2 cm in diameter in her right breast. A biopsy revealed an invasive ductal breast carcinoma. Breast-preserving surgery with segmental resection and dissection of the right axilla was performed. None of the 12 axillary lymph nodes examined had metastatic involvement. Local radiotherapy and adjuvant chemotherapy were administered.

The patient remained free of disease for 5 years. In December 1995, she was referred to the dermatology clinic because of progressive swelling of the right upper and lower eyelids of 3 months’ duration. Two months later, several cutaneous nodules appeared on the neck and trunk. On examination, the right upper and lower eyelids were diffusely swollen with reddening of the skin and showed a palpable, homogeneous, firm consistency (Fig. 1).

Biopsy specimens of both the lower right eyelid and a cutaneous nodule on the trunk revealed metastatic carcinoma. The immunohistochemical study was compatible with a primary breast location. Abdominal computed tomographic scan revealed disseminated liver metastases. A bone scan showed intense accumulations in the left clavicle, fourth dorsal vertebra and several ribs. Serum mucinous-like carcinoma antigen levels were markedly elevated. According to the patient’s wishes, only symptomatic, palliative treatment was given. She died 4 months after the diagnosis of eyelid metastasis.

Metastasis to the eyelids is rare, accounting for less than 1% of malignant eyelid lesions.4,5 Breast carcinoma accounts for 35–65% of cases in different series. In a recent review of the literature, Zhang et al.6 found only 36 cases of eyelid metastasis from breast cancer. The site of the eyelid metastasis was the right side in 22 cases (61%), as observed in our patient. The reason for preferential involvement of the right eyelid, if any, is unknown. Eyelid metastasis often occurs in the advanced stages of malignant tumours, and they are usually a sign of poor prognosis. Among the 36 previously reported cases from breast cancer, only nine (25%) showed metastasis of the eyelid alone at presentation.

Riley has classified eyelid metastasis into three types according to clinical features.7 Type 1 show solitary subcutaneous nodules, non-tender and non-inflamed. Fifteen of 37 (41%) reported cases of breast eyelid metastasis had this type of clinical presentation. Solitary nodules may be mistaken clinically for chalazion. Type 2 is a non-tender thickening and

Figure 2. Photomicrograph showing amorphous calcified debris surrounded by foreign body giant cells (haematoxylin and eosin: ×25).
induration in the eyelid, which is typically observed in breast carcinoma. This type has been observed in 22 cases (59%) of eyelid metastasis from mammary cancer, including the present case. Type 3 lesions are ulcerative. This type has not been reported so far for breast carcinoma metastasis to the eyelid.

Departments of Dermatology and Pathology, La Paz University Hospital, Pasio Castellana 261, 28046 Madrid, Spain
F. A. Rubio, A. Pizarro, G. Robana, M. Mayor, I. Buron, F. Contreras*, M. Caseño

References

Necrolytic migratory erythema-like eruption in zinc deficiency associated with alcoholic liver disease

Sr., We read with interest the paper by Sinclair and Reynolds on necrolytic migratory erythema (NME) and zinc deficiency. We would like to point out that, in patients with alcoholic liver disease, a pseudoglucagonoma syndrome is highly suggestive of zinc deficiency. In northern France, alcoholic cirrhosis is frequent, and we are interested in its cutaneous manifestations. Over the last few years, we have had the opportunity to see several patients with advanced cirrhosis. Certain patients develop an extensive, scaling, erosive dermatitis (Figs 1 and 2a) involving predominantly the peri-orificial areas (Fig. 2b) but also the limbs and the trunk, and associated with bilateral angular cheilitis and glossitis. Skin biopsies specimens showed similar histopathological findings of parakeratosis, acanthosis, necrosis of upper epidermal keratinocytes and a lymphocytic infiltrate in the papillary dermis. Plasma glucagon levels were always normal and no glucagonomas were detected. Plasma zinc levels were decreased or just below the normal range, and a dramatic improvement was observed in all patients with zinc therapy. Sub-normal levels of plasma zinc do not discount the presence of zinc deficiency. Indeed, only leucocyte zinc concentrations seem to correlate closely with zinc tissue status.

Zinc deficiency may present not only with asteatotic eczema or acrodermatitis enteropathica, but also with a NME-like eruption. It seems likely that some reported cases of NME without glucagonoma in patients with small bowel disorder, or liver disease, may have been examples of zinc deficiency. In these patients, zinc supplements are best given intravenously. In the absence of improvement after 1 week of treatment, essential fatty acids deficiency must be considered.

Figure 1. A widespread cutaneous eruption is evident with circinate and serpiginous borders.

© 1997 British Association of Dermatologists, British Journal of Dermatology. 137, 1011–1031
Trimethoprim-induced linear fixed drug eruption

SIR. We present a patient with a linear fixed drug eruption (FDE) caused by trimethoprim. A 25-year-old Caucasian woman was referred with a pruritic linear eruption on her right arm. Examination revealed numerous discrete, round–oval-shaped, violaceous macules and oedematous plaques of 1–5 cm diameter distributed in a linear pattern on the right arm (Fig. 1), extending from the lateral aspect of the dorsum of the fourth and fifth fingers, along the wrist and the extensor surface of the forearm, across the elbow, and up to the right shoulder. Some of the lesions were surmounted by flaccid bullae. This was her third attack in 6 months. Lesions lasted for 10–15 days and healed with residual pigmentation. She had a history of co-trimoxazole intake on the day before the eruption had begun and also of occasional intake during the last 2–3 years because of relapsing tonsillitis. No systemic abnormalities were found on physical and routine laboratory examination. Histopathological examination revealed epidermal spongiosis, exocytosis and dyskeratosis, hydropic degeneration in the epidermal basal layer, pigimentary incontinence, and a mononuclear perivascular inflammatory infiltration with single eosinophils and neutrophils in the upper and mid-dermis, all of which supported the diagnosis of FDE.

After withdrawal of cotrimoxazole and treatment with methylprednisolone 32 mg/day orally for 3 days, lesions cleared leaving residual hyperpigmentation. Four weeks later, an oral challenge with one-eighth of a single co-trimoxazole dose was performed. The previously involved FDE sites reactivated completely with marked violaceous erythema and oedema starting within 1–2 h, and progressed into flaccid bullae (Fig. 2). Four weeks later, topical provocation tests were performed. Tape-stripping occlusive patch testing with co-trimoxazole, trimethoprim and sulphamethoxazole at concentrations of 10%, 20% and 50% in white petrolatum, with pure petrolatum as the negative control, gave no reaction on previously involved and uninvolved skin. In a repeated open application patch test with the drugs at the same concentrations in dimethyl sulphoxide (DMSO), a positive reaction was seen on previously involved skin sites with trimethoprim 50%
and co-trimoxazole 20% and 50%, starting \(\approx 4-5 \text{ h}\) after the second application of the test preparations.

Several less common clinical types of FDE have been reported, with urticarial, nodular, eczematous and erythema multiforme-like lesions, \(^1,2\) and unusual appearance such as symmetrical pigmenting, non-pigmenting, wandering and pulsating lesions, thoracic lesions following the line of intercostal nerves, and central trunk lesions straddling the mid-line symmetrically. \(^1,4\) Recently, a single case with a peculiar linear distribution pattern of FDE lesions on the leg due to intramuscular injection of cephazolin was reported. \(^4\)

Several explanations can be found for the linear distribution of the FDE lesions. In the literature, various skin changes have been reported following a linear pattern. \(^5\) This linearity may be related to the distribution of the dermatomes, Blaschko’s lines, tension lines and anatomical structures, and to the Köbner phenomenon occurring after prior injuries or inflammatory reactions such as insect bites, healed herpes zoster or previous cellulitis. \(^5\) On the extremities, Blaschko’s lines and the dermatomes run in a linear pattern and it is difficult to decide whether the skin lesions are consistent with one or the other. The linearity of the previous case of linear FDE on the left leg after intramuscular injection of cephazolin was attributed to the dermatomal distribution of \(S_1\) nerve roots rather than to Blaschko’s lines. \(^4\) The linearity in our patient may be related either to the distribution along the \(C_8\) dermatomal region or Blaschko’s lines.

Systemic provocation is still the most reliable method for establishing the causal agent in drug reactions. However, a topical provocation would be safer and easier to apply as a screening test especially when multiple drugs are suspected. Topical provocation tests with cephazolin (10% in white petrolatum, lanolin–petrolatum and glycerine) as an open application which was described by Alanko remained negative in the previously reported case with linear FDE. A systemic provocation with cephazolin was not performed. \(^4\)

In Turkey, \(\approx 80\%\) of FDE cases are co-trimoxazole related (unpublished data). In most of the studies reported from other countries, sulphamethoxazole is regarded as the main cause of co-trimoxazole allergy, but reactions to trimethoprim have also been reported. \(^6-8\) Usually, the offending drugs are determined by means of oral challenge. Topical provocation and positive reactions with co-trimoxazole are extremely rare in the literature. \(^9-11\) Alanko et al. pointed out that topical provocation with trimethoprim and sulphamethoxazole can best be obtained when DMSO is used as vehicle. \(^9\)

To the best of our knowledge, our report represents the second linear FDE case in the literature. We would therefore point out that FDE should also be considered in the differential diagnosis of skin diseases with a linear distribution pattern, especially when there is a definite history of the lesions recurring in the same sites.

I.Ü. Istanbul Tip Fakültesi, E.ÖZKAYA-BAYAZIT
Dermatoloji Anabilim Dali,
34390 Çağla-Istanbul, Turkey
Email: bayazit@turk.net

References

Livedoid skin necrosis (Nicolau syndrome) due to triple vaccine (DTP) injection

SIR, Nicolau syndrome is a rare entity that consists of the development of cutaneous, subcutaneous, and even muscular necrosis with a livedoid pattern, shortly after intramuscular injection of many different drugs. We report the first case of this entity due to the intramuscular injection of diphtheria, tetanus and pertussis (DTP) vaccine.

A 3-month-old boy, without any remarkable past medical history, received the first intramuscular dose of vaccine against DTP in the anterior aspect of his left thigh. Immediately after the injection, the child showed intense irritability, probably related to local pain. An oedematous, pale plaque appeared at the injection site, and he was consequently admitted to our hospital. Three hours after the injection, the lesion had evolved into a livedoid purplish patch with dendritic extensions. The child was otherwise in general good health and routine laboratory examinations showed no abnormalities. A skin biopsy specimen was obtained. Histological examination disclosed necrosis of the eccrine glands, and thrombosis involving vessels of medium and small size of the reticular dermis without vasculitis. Twenty-four hours later the lesion was a well-defined, reticulate, violaceous patch (Fig. 1). The lesion was treated with local disinfection and topical mupirocin ointment. Progressively, three small eschars appeared and on the 10th day he was discharged. The general status of the child remained unaltered throughout the evolution. After 1 month, the lesion had completely healed leaving a slightly atrophic scar. The second dose of DTP was administered at the sixth month of life without immediate or delayed untoward reactions.

In the 1920s, livedoid skin necrosis was a well-known adverse effect of bismuth salts routinely used for the treatment of syphilis.1–3 Later, the phenomenon was related to intramuscular injection of antirheumatic preparations containing phenylbutazone associated or not with other anti-inflammatory agents, local anaesthetics (lignocaine), antihistamines (diphenhydramine), corticosteroids (triamcinolone), or vitamin B complexes (cyanocobalamin).4 It has also been described, as isolated cases, with antibiotics such as sulphonamides, benzantine penicillin, procaine penicillin G, pyrazolone, chlorpromazine, camphor-quinine combinations, phenobarbitone, recombinant interferon-α and a mixture of sedatives (meperidine, promethazine and chlorpromazine).5

Multiple pathogenic mechanisms have been proposed. The most reasonable hypothesis points to a vascular origin. Embolia cutis medicamentosa would be the end result of intra-arterial or periarterial injection of the offending drug, with subsequent arterial vasospasm and cutaneous necrosis with a livedoid pattern. Experimental animal models have shown that intravascular injections can produce thrombosis or vasospasm, followed by inflammation of the vessel wall. Complete destruction of the vessel and necrosis of irrigated tissues may ensue.6 Hence, this syndrome should be considered as a consequence of direct trauma or irritation of vascular structures. Thus, elicitation of a new episode of livedoid skin necrosis after a further dose of the causative drug is not to be expected, as it would be if an immunoallergic mechanism were operating. Moreover, experimental studies have not provided data supporting the immunological hypothesis.7 Nevertheless, in spite of the traumatic/irritative origin being the most feasible, experimental
data suggesting some relation with injection technique\(^{8}\) and pH of the injected solution\(^{7}\) are lacking.

This patient is, to our knowledge, the youngest child to suffer from livedoid skin necrosis and the first case due to injection of DTP. None the less, it is unexplained why embolia cutis medicamentosa is so rare in children, as almost all children in the world are currently vaccinated against DTP by intramuscular injection. In our case, the second dose did not reproduce this adverse effect, suggesting that immunological or allergic factors do not play any significant part.

Department of Dermatology and *Pathology, Hospital del Niño Jesús, Avda Mene\'ndez Pelayo 65, 28009 Madrid, Spain

E. Nagore, A. Torrelo, I. González-Mediero*, A. Zambrano

References